转移性去势抵抗性前列腺癌治疗领域的变化。
The changing landscape in the treatment of metastatic castration-resistant prostate cancer.
机构信息
Division of Hematology and Oncology, Department of Medicine, George Washington University Medical Center, Washington, DC, USA.
出版信息
Ther Adv Med Oncol. 2013 Jan;5(1):25-40. doi: 10.1177/1758834012458137.
Abstract
The past few years have brought increasing advances in the therapeutic management of metastatic castration-resistant prostate cancer with the approval of several agents, including vaccine therapy with sipuleucel-T, second-line chemotherapy with cabazitaxel, the bone-targeted pharmaceutical denosumab, and the novel antiandrogen therapy abiraterone acetate. There are ongoing developments with other agents in the pipeline such as MDV3100 and alpharadin that have shown promising results. This review describes the clinical trials that brought about the drug approvals of various agents and offers some insights regarding a rational approach to optimal treatment sequencing for these drugs since national guidelines are currently lacking.
摘要
过去几年，随着几种药物的批准，转移性去势抵抗性前列腺癌的治疗管理取得了越来越多的进展，包括 sipuleucel-T 的疫苗治疗、卡巴他赛的二线化疗、骨靶向药物地舒单抗和新型抗雄激素治疗醋酸阿比特龙。其他药物如 MDV3100 和 alpharadin 也在研发中，显示出了有前景的结果。本文综述了带来各种药物批准的临床试验，并就这些药物的最佳治疗顺序的合理方法提供了一些见解，因为目前缺乏国家指南。
相似文献
1
The changing landscape in the treatment of metastatic castration-resistant prostate cancer.转移性去势抵抗性前列腺癌治疗领域的变化。
Ther Adv Med Oncol. 2013 Jan;5(1):25-40. doi: 10.1177/1758834012458137.
2
A changing landscape in castration-resistant prostate cancer treatment.去势抵抗性前列腺癌治疗领域的变化。
Front Endocrinol (Lausanne). 2012 Jul 18;3:85. doi: 10.3389/fendo.2012.00085. eCollection 2012.
3
Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.治疗转移性去势抵抗性前列腺癌患者：现有疗法的全面综述
J Urol. 2015 Dec;194(6):1537-47. doi: 10.1016/j.juro.2015.06.106. Epub 2015 Jul 18.
4
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.局部晚期和转移性前列腺癌的系统治疗进展：精准肿瘤学时代下转移性去势抵抗性前列腺癌的管理。
Eur Urol. 2019 Jan;75(1):88-99. doi: 10.1016/j.eururo.2018.03.028. Epub 2018 Apr 16.
5
Management of metastatic castration-resistant prostate cancer.转移性去势抵抗性前列腺癌的管理
Eur Urol Rev. 2011 Winter;6(2):90-96.
6
Metastatic castration resistant prostate cancer: current strategies of management in the Middle East.转移性去势抵抗性前列腺癌：中东地区当前的管理策略
Crit Rev Oncol Hematol. 2014 Apr;90(1):36-48. doi: 10.1016/j.critrevonc.2013.11.001. Epub 2013 Nov 8.
7
Novel options for the treatment of castration-resistant prostate cancer.治疗去势抵抗性前列腺癌的新选择。
World J Urol. 2012 Aug;30(4):495-503. doi: 10.1007/s00345-011-0796-7. Epub 2011 Nov 20.
8
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.EAU-ESTRO-SIOG 前列腺癌诊治指南。第二部分：复发、转移和去势抵抗性前列腺癌的治疗。
Eur Urol. 2017 Apr;71(4):630-642. doi: 10.1016/j.eururo.2016.08.002. Epub 2016 Aug 31.
9
Metastatic castration-resistant prostate cancer: time for innovation.转移性去势抵抗性前列腺癌：创新之时
Future Oncol. 2015;11(1):91-106. doi: 10.2217/fon.14.145.
10
Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?晚期前列腺癌的治疗选择：Sipuleucel-T 的作用是什么？
Clin Med Insights Oncol. 2011;5:325-32. doi: 10.4137/CMO.S5977. Epub 2011 Oct 20.
引用本文的文献
1
P2Y1 agonist HIC in combination with androgen receptor inhibitor abiraterone acetate impairs cell growth of prostate cancer.P2Y1 激动剂 HIC 联合雄激素受体抑制剂醋酸阿比特龙可抑制前列腺癌细胞生长。
Apoptosis. 2022 Apr;27(3-4):283-295. doi: 10.1007/s10495-022-01716-1. Epub 2022 Feb 7.
2
Docetaxel and Doxorubicin Codelivery by Nanocarriers for Synergistic Treatment of Prostate Cancer.纳米载体共递送多西他赛和阿霉素用于前列腺癌的协同治疗
Front Pharmacol. 2019 Dec 18;10:1436. doi: 10.3389/fphar.2019.01436. eCollection 2019.
3
Systematically understanding the immunity leading to CRPC progression.系统性理解导致 CRPC 进展的免疫。
PLoS Comput Biol. 2019 Sep 10;15(9):e1007344. doi: 10.1371/journal.pcbi.1007344. eCollection 2019 Sep.
4
Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer: Practical Management Issues for Patient Selection.镭-223 治疗去势抵抗性前列腺癌骨转移：患者选择的实用管理问题。
Am J Clin Oncol. 2019 Apr;42(4):399-406. doi: 10.1097/COC.0000000000000528.
5
Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer.克服前列腺癌恩杂鲁胺耐药性的机制与方法
Front Oncol. 2018 May 24;8:180. doi: 10.3389/fonc.2018.00180. eCollection 2018.
6
Imaging and treatment recommendations in patients with castrate-resistant prostate cancer.去势抵抗性前列腺癌患者的影像学检查及治疗建议
Rev Urol. 2017;19(3):200-202. doi: 10.3909/riu193PracticeProfile.
7
Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer.靶向转移性去势抵抗性前列腺癌中的骨转移
Clin Med Insights Oncol. 2016 Mar 23;10(Suppl 1):11-9. doi: 10.4137/CMO.S30751. eCollection 2016.
8
Radioimmunotherapy of prostate cancer targeting human kallikrein-related peptidase 2.靶向人激肽释放酶相关肽酶2的前列腺癌放射免疫疗法
EJNMMI Res. 2016 Dec;6(1):27. doi: 10.1186/s13550-016-0181-z. Epub 2016 Mar 17.
9
A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer.索拉非尼和尼洛替尼联合使用可降低去势抵抗性前列腺癌的生长。
Int J Nanomedicine. 2016 Jan 8;11:179-200. doi: 10.2147/IJN.S97286. eCollection 2016.
10
Health Economics and Radium-223 (Xofigo®) in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Case History and a Systematic Review of the Literature.卫生经济学与镭-223（Xofigo®）治疗转移性去势抵抗性前列腺癌（mCRPC）：病例报告及文献系统综述
Glob J Health Sci. 2015 Jul 30;8(4):1-9. doi: 10.5539/gjhs.v8n4p1.
本文引用的文献
1
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.随机、双盲、安慰剂对照 III 期临床试验比较多西他赛和泼尼松与或不与贝伐珠单抗在转移性去势抵抗性前列腺癌男性患者中的疗效：CALGB 90401。
J Clin Oncol. 2012 May 1;30(13):1534-40. doi: 10.1200/JCO.2011.39.4767. Epub 2012 Mar 26.
2
Chemotherapy and immunotherapy combination in advanced prostate cancer.晚期前列腺癌的化疗与免疫治疗联合应用
Clin Adv Hematol Oncol. 2012 Feb;10(2):90-100.
3
Optimizing outcomes of advanced prostate cancer: drug sequencing and novel therapeutic approaches.优化晚期前列腺癌的治疗效果：药物序贯治疗与新型治疗方法。
Oncology (Williston Park). 2012 Jan;26(1):70-7.
4
Rationing in urologic oncology: lessons from sipuleucel-T for advanced prostate cancer.泌尿外科肿瘤学中的配给制：晚期前列腺癌中 sipuleucel-T 的经验教训。
Urol Oncol. 2013 Oct;31(7):1079-84. doi: 10.1016/j.urolonc.2011.12.022. Epub 2012 Feb 4.
5
ARN-509: a novel antiandrogen for prostate cancer treatment.ARN-509：一种用于前列腺癌治疗的新型抗雄激素药物。
Cancer Res. 2012 Mar 15;72(6):1494-503. doi: 10.1158/0008-5472.CAN-11-3948. Epub 2012 Jan 20.
6
Cancer statistics, 2012.癌症统计数据，2012 年。
CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29. doi: 10.3322/caac.20138. Epub 2012 Jan 4.
7
Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.前列腺癌去势抵抗治疗中 sipuleucel-T 的免疫治疗的跨学科批判。
J Natl Cancer Inst. 2012 Feb 22;104(4):273-9. doi: 10.1093/jnci/djr514. Epub 2012 Jan 9.
8
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial.地舒单抗与去势抵抗性前列腺癌患者的骨转移无进展生存：一项 3 期、随机、安慰剂对照试验的结果。
Lancet. 2012 Jan 7;379(9810):39-46. doi: 10.1016/S0140-6736(11)61226-9. Epub 2011 Nov 15.
9
Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.奥替隆（TAK-700）的发现，一种萘基甲基咪唑衍生物，作为一种高度选择性的 17,20-裂解酶抑制剂，具有治疗前列腺癌的潜在用途。
Bioorg Med Chem. 2011 Nov 1;19(21):6383-99. doi: 10.1016/j.bmc.2011.08.066. Epub 2011 Sep 1.
10
Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.二期随机、双盲、安慰剂对照研究在有轻微症状的转移性去势抵抗性前列腺癌男性中使用塔昔单抗。
J Clin Oncol. 2011 Oct 20;29(30):4022-8. doi: 10.1200/JCO.2011.35.6295. Epub 2011 Sep 19.
Zotero 插件